Effect of Papillary Epinephrine Spraying for the Prevention of Post-ERCP Pancreatitis in Patients Received Octreotide
Effect of Papillary Epinephrine Spraying for the Prevention of Post-ERCP Pancreatitis in Patients Received Octreotide
Post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) is the most
 common complication with high costs, significant morbidity and even mortality. The major
 mechanisms of PEP is the papillary edema which is caused by manipulations during cannulation
 or endoscopic treatment. The papillary edema may cause temporary outflow obstruction of
 pancreatic juice, and then increase ductal pressure, resulting in the occurrence of
 pancreatitis. Nitroglycerin can reduce the Oddis sphincter tension, the internal pressure of
 the biliary tract and the pancreatic duct. Therefore, it is widely used in clinical to
 prevent and treat pancreatitis. Many studies found nitroglycerin might be effective in
 preventing PEP. And topical application of epinephrine on the papilla may reduce papillary
 edema by decreasing capillary permeability or by relaxing the sphincter of Oddi. There are
 reports that epinephrine sprayed on the papilla may be effective to prevent PEP.

 The investigators therefore designed a prospective randomized trial to determine whether
 routine using papillary epinephrine spraying in patients received octreotide can reduce
 post-ERCP pancreatitis.
Inclusion Criteria:

 1. ERCP surgery is required

 2. Signed inform consent form and agreed to follow-up on time.

 Exclusion Criteria:

 1. Acute pancreatitis.

 2. Pregnancy or history of allergy to epinephrine.

 3. Serious liver, kidney, heart and coagulation disorders

 4. Unwilling or inability to provide consent